← Leaderboards
William G Hawkins
Washington University
$8,815,633
Attributed
$11,122,287
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,340,726 · 10
By mechanism
P50$19,373,754 · 6
R01$4,575,348 · 2
R42$2,033,915 · 1
R21$357,709 · 1
Top collaborators
- Dirk M. Spitzer8 shared
- David G Denardo2 shared
- Bradley T. Keller2 shared
- Kian H Lim2 shared
Most similar at Washington University
Same institution · by research overlap
- Dirk M. Spitzer$1,509,975
- Delphine L Chen$4,481,188
- Andrew Eric Gelman$12,797,349
- Megan Deanna Radyk$377,301
- Jonathan Edward McConathy$1,853,535
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasMalignant NeoplasmsTumorNovel StrategiesLigandsIn VivoInnovationClinical TrialsWashingtonPharmaceutical PreparationsUniversitiesIn VitroCell DeathDesignToxic EffectPre-ClinicalResistancePancreatic Ductal AdenocarcinomaSigma-2 ReceptorApoptosisPancreatic AdenocarcinomaNeoplastic CellSmall MoleculeDrug Development
Grant awards (41)
Washington University SPORE in Pancreatic Cancer$2,178,396
P50 · FY2025 · CA
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC$355,885
P50 · FY2025 · CA · contact PI
Core A: Administrative Core$215,097
P50 · FY2025 · CA · contact PI
Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy$180,811
R01 · FY2025 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,091,214
P50 · FY2024 · CA
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC$341,650
P50 · FY2024 · CA · contact PI
Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy$325,083
R01 · FY2024 · CA
Core A: Administrative Core$206,492
P50 · FY2024 · CA · contact PI
Preclinical development of the novel inhibitor of apoptosis proteins S2/IAPinh for cancer therapy$12,839
R01 · FY2024 · CA
Preclinical development of the novel inhibitor of apoptosis proteins S2/IAPinh for cancer therapy$346,659
R01 · FY2023 · CA
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC$336,881
P50 · FY2023 · CA · contact PI
Core A: Administrative Core$131,302
P50 · FY2023 · CA · contact PI
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)$1,019,186
R42 · FY2022 · CA
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)$1,014,729
R42 · FY2021 · CA
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2021 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,184,707
P50 · FY2020 · CA · contact PI
Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW v-49$473,179
P50 · FY2020 · CA · contact PI
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2020 · CA · contact PI
Core A: Administrative Core$70,866
P50 · FY2020 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,134,321
P50 · FY2019 · CA · contact PI
Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW v-49$440,697
P50 · FY2019 · CA · contact PI
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$369,812
R01 · FY2019 · CA · contact PI
Core A: Administrative Core$163,018
P50 · FY2019 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,300,000
P50 · FY2018 · CA · contact PI
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2018 · CA · contact PI
Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW v-49$344,339
P50 · FY2018 · CA · contact PI
Core A: Administrative Core$175,175
P50 · FY2018 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,143,077
P50 · FY2017 · CA · contact PI
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2017 · CA · contact PI
Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW v-49$312,611
P50 · FY2017 · CA · contact PI
Core A: Administrative Core$151,908
P50 · FY2017 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,186,724
P50 · FY2016 · CA · contact PI
Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW v-49$392,579
P50 · FY2016 · CA · contact PI
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER$371,287
R01 · FY2016 · CA · contact PI
Core A: Administrative Core$43,636
P50 · FY2016 · CA · contact PI
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER$371,287
R01 · FY2015 · CA · contact PI
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER$360,148
R01 · FY2014 · CA · contact PI
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER$337,151
R01 · FY2013 · CA · contact PI
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER$375,271
R01 · FY2012 · CA · contact PI
ON THE TRAIL TO PANCREAS CANCER-SELECTIVE TUMOR CELL DEATH (APOPTOSIS)$192,409
R21 · FY2011 · CA · contact PI
ON THE TRAIL TO PANCREAS CANCER-SELECTIVE TUMOR CELL DEATH (APOPTOSIS)$165,300
R21 · FY2010 · CA · contact PI